🚀 $RNAC: mRNA Biotech with Q1 Catalyst & Fresh Cash. 5-10x Potential 💎 🙌

🚀 **RNAC - mRNA Biotech Rocket Ready for Liftoff** 🌕

Alright fellas, while the market chases tech hype, $RNAC is at $7.50 and building something real in autoimmune diseases with massive upside potential.

**The Bull Case:**

**Fresh rocket fuel**: Just announced (days ago) up to $150M non-dilutive financing ($50M upfront) on May 26, extending cash runway into 2028 with minimal dilution.

**Game-changing tech**: Descartes-08 is an autologous mRNA CAR-T for autoimmune conditions like myasthenia gravis (gMG). No viral vectors, no heavy chemo, outpatient dosing, and repeatable. A safer, better approach than traditional CAR-T.

**Strong Phase 2b results**: Deep and durable responses with 7+ point MG-ADL improvements lasting up to 12 months. Patients saw major, lasting benefits.

**Big catalysts ahead**: Phase 3 AURORA trial in gMG is enrolling, topline data expected Q1 2027. FDA SPA agreement secured. Potential BLA filing mid-2027.

**Experienced leadership**: CEO Carsten Brunn, Ph.D. (also Chairman) brings 25+ years of global pharma expertise from Bayer (President of Americas and Japan), Eli Lilly, Novartis, and more. Proven track record in leading clinical programs and commercial strategy through the Selecta merger — well-positioned to navigate Phase 3 and potential commercialization or partnerships.

**Analysts**: Strong Buy ratings. Wedbush Outperform at $38. Average targets $34–36 (5x upside). Market cap still tiny at $220M.

This is a de-risked biotech with data and a clear path forward. If Phase 3 succeeds, it’s likely a 5-10x bagger **Diamond hands until readout or buyout.** 💎** **🙌** **

**TL;DR: RNAC = Innovative mRNA biotech + experienced leadership + cash secured + strong data + Phase 3 catalyst in Q1 2027 = 5x upside potential.**